APX and Revelle Enter Strategic Partnership
The partnership between APX and Revelle aims to help aesthetic practices accelerate growth and productivity.
The partnership between APX and Revelle aims to help aesthetic practices accelerate growth and productivity.
Available in the EU, UK, and Switzerland, the device is designed for in-office preparation of autologous PRP and Fluid-PRF.
A clinical trial involving 828 patients found that three weeks of radiation following mastectomy did not increase reconstruction complications compared with the standard five-week course.